ASH Statement in Support of Palliative Blood Transfusions in Hospice Setting
Jun 25, 2019
As an organization of physicians and scientists who care for desperately ill patients, including those with blood cancers such as leukemia, lymphoma, and myeloma, as well as those with non-malignant conditions such as sickle cell disease, thalassemia, hemophilia, thrombophilia, and various anemias, ASH is supportive of efforts to ensure patients have access to appropriate care throughout the course of their disease, including those receiving hospice care.
Statement on Opioid Use in Patients with Hematologic Diseases and Disorders
Apr 18, 2018
ASH is alarmed about the opioid crisis; however, it is concerned about potential adverse effects that policy changes could have on the administration of necessary and appropriate pain medicine for patients with hematologic conditions such as sickle cell disease (SCD), blood cancers, and other bleeding disorders.
ASH Policy Statement in Support of Patient Access to Safe and Effective Drugs
Jan 06, 2017
As an organization of physicians and scientists who care for desperately ill patients, including those with blood cancers such as leukemia, lymphoma, and myeloma, the American Society of Hematology (ASH) is supportive of efforts to provide insurance parity for all approved evidence-based cancer treatments.
Patient Advisory for Stem Cell Therapy and Medical Tourism
Aug 19, 2013
As stakeholders in cellular therapy, the undersigned professional organizations believe it is necessary to share the following important message with patients and families contemplating cell therapy or experimental stem cell procedures.
ASH Agenda for Hematology Research 2012-2014 Summary
May 04, 2012
Funding for hematology research is an investment in the nation’s health. Research funding must increase to allow the major advances in understanding the molecular defects behind a hematologic disease to be translated into novel diagnostics and targeted therapeutics. Given the broad benefits that will be derived from this research, federal agencies should coordinate their hematology funding in order to produce the greatest impact on specific high-need areas. A multi-agency approach would deliver advances faster, more economically, and more efficiently.
2012-2014 ASH Agenda for Hematology Research
Apr 24, 2012
Despite impressive progress in understanding and treating hematologic disease, significant challenges remain, as each new discovery illustrates how much more we have yet to learn. The challenge now is to translate these new discoveries into patient care that delivers better survival, less toxicity, and even disease prevention.
Statement on Screening for Sickle Cell Trait and Athletic Participation
Jan 26, 2012
The American Society of Hematology Policy Statement on Screening for Sickle Cell Trait and Athletic Participation opposes mandatory screening of athletes for sickle cell trait as a prerequisite to athletic participation and urges athletics programs to adopt universal preventive interventions in their training programs to protect all athletes from exertion-related illness and death.
Frequently Asked Questions Regarding Sickle Cell Trait
Jan 25, 2012
A list of Frequently Asked Questions regarding sickle cell trait for both medical experts and consumers/patients.
Statement in Support of All Avenues of Stem Cell Research
Oct 18, 2010
As an organization of physicians who care for desperately ill patients and scientists devoted to understanding the basic mechanisms of disease and discovering new therapies, the American Society of Hematology (ASH) is excited about the scientific potential of all avenues of stem cell research, particularly human embryonic stem cells (hESC), adult stem cells, and induced pluripotent cells (iPS) derived by gene modifications of adult cells.
Statement on Clinical Research and Trials
Sep 16, 2010
Clinical research in hematology has never been more important, yet clinical hematology investigators are facing unprecedented challenges. Constantly changing and often inconsistent regulations, chaotic reimbursement policies, lack of insurance coverage of routine care associated with clinical trials, increasing demands on physician time, and scientific advances demonstrating the complex differences between individual patients, all complicate clinical research in both benign and malignant hematology.